Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

Beta‐blockers + sclerotherapy(1 RCT, 141 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding

It is very uncertain whether the intervention changes beta‐blockers + sclerotherapy(1 RCT, 141 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Beta‐blockers plus Sclerotherapy(No direct RCT) · people with liver cirrhosis and previous oesophageal variceal bleeding

It is very uncertain whether the intervention changes beta‐blockers plus Sclerotherapy(No direct RCT) (very low certainty).

1 finding from 1 review

Intervention not reported

Beta‐blockers plus Sclerotherapy(2 RCTs; 71 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding

The intervention showed no clear difference in beta‐blockers plus Sclerotherapy(2 RCTs; 71 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Beta‐blockers plus Sclerotherapy(2 RCTs; 128 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding

The intervention showed no clear difference in beta‐blockers plus Sclerotherapy(2 RCTs; 128 participants) (low certainty).

1 finding from 1 review

Intervention not reported

Beta‐blockers plus Sclerotherapy(1 RCT; 40 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding

It is very uncertain whether the intervention changes beta‐blockers plus Sclerotherapy(1 RCT; 40 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Beta‐blockers plus sclerotherapy(4 RCTs; 231 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding

The intervention probably leads to lower beta‐blockers plus sclerotherapy(4 RCTs; 231 participants) (moderate certainty).

1 finding from 1 review

Intervention not reported

Beta‐blockers plus Sclerotherapy(8 RCTs; 370 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding

The intervention showed no clear difference in beta‐blockers plus Sclerotherapy(8 RCTs; 370 participants) (low certainty).

1 finding from 1 review

Sunlight (with or without filters or amplification) vs no treatment

Use of conventional phototherapy, if sunlight (with or without filters or amplification) was first used for prevention or early treatmentc · term and late preterm neonates

The review found no eligible studies for this question.

1 finding from 1 review

Bamlanivimab vs placebo

Clinical progression: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7) · hospitalised individuals with COVID‐19 (moderate to severe disease)

It is very uncertain whether bamlanivimab changes clinical progression: need for NIV, IMV, ECMO, or renal replacement… compared with placebo (very low certainty).

1 finding from 1 review

Levamisole vs cyclophosphamide

Relapse · SSNS in children

It is very uncertain whether levamisole changes relapse: at end of therapy compared with cyclophosphamide (very low certainty).

4 findings from 1 review
Show 1 more finding